Related Experiment Video
Updated: Aug 15, 2026
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Poor formulation information in published pediatric drug trials
Joseph F Standing1, Zahra F Khaki, Ian C K Wong
1School of Pharmacy, University of London, London, United Kingdom.
Insights
Pediatric drug trials often lack adequate formulation information, hindering reproducibility and clinical use. Authors must report full formulation details to ensure the validity and reliability of pediatric medication studies.
Area of Science:
- Pediatric Pharmacology
- Clinical Trial Methodology
- Pharmaceutical Sciences
Background:
- International Conference on Harmonisation guidelines recommend appropriate formulations for pediatric drug trials.
- Economic constraints and limited formulation research often lead to the use of non-ideal formulations in pediatric studies.
- Accurate reporting of formulation and administration methods is crucial for the reliability and validity of pediatric drug trial results.
Purpose of the Study:
- To evaluate the adequacy of pediatric drug formulation information reported in recently published clinical trials involving children under 12 years of age.
- To assess whether published pediatric oral medication studies provide sufficient detail for accurate reproduction and clinical implementation.
Main Methods:
- A hand-search of 3992 papers published between July 2002 and June 2004 in 10 highly cited journals (5 pediatric, 5 general medicine) was conducted.
- Two independent reviewers extracted data on drug formulation and administration for oral medication studies including children younger than 12 years.
- Papers were classified based on the adequacy of reported formulation information: adequate, some, or none.
Main Results:
- Of 76 eligible studies, only 28 (37%) provided adequate formulation information for accurate reproduction.
- Twenty-six percent (20/76) of studies failed to report the formulation used.
- Among studies reporting formulation, only 49% (37/76) utilized a pediatric-specific formulation (e.g., liquid, chewable tablet).
- No significant differences in reporting adequacy were observed between pediatric and general medical journals.
Conclusions:
- Highly cited journals frequently publish pediatric drug trial reports with inadequate formulation details, compromising study validity and reliability.
- Authors are urged to consistently provide comprehensive formulation information in all pediatric clinical trial publications.
- Improved reporting standards are necessary to enhance the clinical applicability and reproducibility of pediatric medication research.
Objective:
The International Conference on Harmonisation Steering Committee recommends that appropriate formulations be used in pediatric drug trials. However, a lack of formulation research and/or economic constraints means that appropriate formulations are not always used. It is important for investigators who report the results of pediatric drug trials to provide sufficient information on the formulation and method of administration to ensure that the results can be reproduced in other clinical studies (reliability) and, more important, implemented in clinical practice (validity). The objective of this study was to evaluate whether pediatric formulation information was adequately reported in recent published trials of oral medicines that included children who were younger than 12 years.
Methods:
Studies that were published between July 2002 and June 2004 in 10 highly cited journals (5 pediatric and 5 general medicine) were hand-searched and data were extracted independently by 2 reviewers according to a protocol. Papers that reported oral medication studies that included children who were younger than 12 years were classified as containing adequate, some, or no information on drug formulation.
Results:
Of 3992 papers reviewed, 76 fulfilled the inclusion criteria. Only 28 (37%) gave adequate information for the study to be reproduced accurately, and 20 (26%) did not state the formulation used. When the formulation was reported, only 37 (49%) studies used a pediatric formulation (liquid, chewable tablet, granules). No significant differences between pediatric and general medical journals were seen, and no single journal consistently met the criteria for adequate information.
Conclusion:
Highly cited journals seem to permit inadequate formulation information in pediatric drug trials that they publish, impairing their validity and reliability. Authors should provide full formulation information in all pediatric clinical trial reports.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:29Drug Dosing: Infants and Children
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism